Catalyst Pharmaceuticals CPRX · NASDAQ
$31.49 -0.02% (-$0.01)
Summary
86 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 31% a year over the last 3 years.
- Out of every 100 USD of revenue, 37 USD is left as net profit.
- It earns 20 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $709.2M against $2.79M.
What to watch
None of the indicators we track raises a caution right now.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 17.4 USD for 1 USD of yearly profit. Over the last five years it was 20.0 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 38% a year over 5 years. Over the last 3 years it grew by 40% a year. Earnings per share grew by 31% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 12
- Hold 4
- Sell 0
No analyst has published a price target.
75% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.